Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103558
Status:
COMPLETED
Last Update Posted:
2015-10-02
First Post:
2005-02-10
Brief Title:
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia CLL
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Phase III Study of Lumiliximab in Combination With Fludarabine Cyclophosphamide and Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label Phase III dose escalation research study of an investigational product called lumiliximab given with FDA Food and Drug Administration approved products fludarabine cyclophosphamide and rituximab FCR The study duration is 17 visits over 42 months or until your disease progresses and you require additional CLL therapy The total duration of participation in the study will be approximately 4 years however your disease status will be followed indefinitely forever
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None